Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2020

View Archived Issues

FDA clears IND application for first-in-human trial of IO-202

FDA approves Tauvid for PET imaging in patients being evaluated for AD

Phenotype detection platform screens for new PD drugs

Tumor types have distinct microbiomes

New alcohol risk genes in Caucasians

A series of benzimidazolones causing rapid degradation of BCL6 as potential therapeutics for DLBCL

New inhibitors of the minichromosomal maintenance protein with potential for the treatment of NSCLC

LMP2 inhibition shows therapeutic potential in AD by protecting against neuroinflammation

Edgewise Therapeutics presents new myosin inhibitors

New JAK-2 inhibitors identified at the Dana-Farber Cancer Institute

Rudong Ringene Pharmaceuticals patents PTPN11 inhibitors

New histone deacetylase inhibitors discovered at Merck & Co.

Genentech and Roche synthesize new RAS protein inhibitors

Novus reports topline phase IIa data on OP-0201 in acute otitis media

Gilead reports phase III data on remdesivir in moderate COVID-19 pneumonia

FDA clears Opko to begin phase II trial of Rayaldee for mild to moderate COVID-19

Ocugen discontinues phase III trial of OCU-300 for ocular graft-versus-host disease

Interim phase Ib data with ALRN-6924 show chemoprotective effect

Avelumab does not show activity in recurrent osteosarcoma trial

FDA approves Brilinta to reduce first heart attack in patients with coronary artery disease

Mesothelin-targeting CAR MCY-M11 appears to be safe in phase I trial

Nicox's NCX-470 enters phase III development

CTI enrolling patients in phase III PREVENT trial of pacritinib in severe COVID-19

Olokizumab obtains first approval in Russia

Phase III study of sulopenem in cUTI does not meet primary endpoint

FDA approves Taltz for active nonradiographic axial spondyloarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...